165 related articles for article (PubMed ID: 21685474)
21. Involvement of the maxillary sinus in bisphosphonate-related osteonecrosis of the jaw: Radiologic aspects.
Wasserzug O; Kaffe I; Lazarovici TS; Weissman T; Yahalom R; Fliss DM; Yarom N
Am J Rhinol Allergy; 2017 Jan; 31(1):36-39. PubMed ID: 28234151
[TBL] [Abstract][Full Text] [Related]
22. Metastatic cancer identified in osteonecrosis specimens of the jaws in patients receiving intravenous bisphosphonate medications.
Carlson ER; Fleisher KE; Ruggiero SL
J Oral Maxillofac Surg; 2013 Dec; 71(12):2077-86. PubMed ID: 23945512
[TBL] [Abstract][Full Text] [Related]
23. Maxilla osseus sequestre and oral exposure: effects of the treatment of multiple myeloma with bisphosphonates.
Lobato JV; Rodrigues JM; Cavaleiro MV; Lobato JM; Xavier L; Santos JD; Maurício AC
Acta Med Port; 2007; 20(2):185-92. PubMed ID: 17868526
[TBL] [Abstract][Full Text] [Related]
24. [Bisphosphonate-related osteonecrosis of the jaw].
Atanes-Bonome P; Atanes-Bonome A; Ríos-Lage P; Atanes-Sandoval AD
Semergen; 2014 Apr; 40(3):143-8. PubMed ID: 24001573
[TBL] [Abstract][Full Text] [Related]
25. Role of intravenous dosage regimens of bisphosphonates in relation to other aetiological factors in the development of osteonecrosis of the jaws in patients with myeloma.
Jarnbring F; Kashani A; Björk A; Hoffman T; Krawiec K; Ljungman P; Lund B
Br J Oral Maxillofac Surg; 2015 Dec; 53(10):1007-11. PubMed ID: 26530732
[TBL] [Abstract][Full Text] [Related]
26. Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid.
Cetiner S; Sucak GT; Kahraman SA; Aki SZ; Kocakahyaoglu B; Gultekin SE; Cetiner M; Haznedar R
J Bone Miner Metab; 2009; 27(4):435-43. PubMed ID: 19240969
[TBL] [Abstract][Full Text] [Related]
27. Jaw avascular osteonecrosis after treatment of multiple myeloma with zoledronate.
Lobato JV; Maurício AC; Rodrigues JM; Cavaleiro MV; Cortez PP; Xavier L; Botelho C; Hussain NS; Santos JD
J Plast Reconstr Aesthet Surg; 2008; 61(1):99-106. PubMed ID: 18068658
[TBL] [Abstract][Full Text] [Related]
28. Osteonecrosis of the Jaw After Bisphosphonates Treatment in Patients with Multiple Myeloma.
Krstevska S; Stavric SG; Cevrevska L; Georgjievski B; Karanfilski O; Sotirova T; Balkanov T
Med Arch; 2015 Dec; 69(6):367-70. PubMed ID: 26843726
[TBL] [Abstract][Full Text] [Related]
29. [Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma].
Lund T; Gregersen H; Vangsted A; Marker P; Abildgaard N
Ugeskr Laeger; 2009 Jan; 171(1-2):50-2. PubMed ID: 19128568
[TBL] [Abstract][Full Text] [Related]
30. Actinomyces Orbital Osteomyelitis in the Setting of Multiple Myeloma and Bisphosphonate-Related Osteonecrosis.
Hu KS; Khanna S
J Neuroophthalmol; 2019 Mar; 39(1):120-121. PubMed ID: 30763286
[No Abstract] [Full Text] [Related]
31. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.
Dimopoulos MA; Kastritis E; Anagnostopoulos A; Melakopoulos I; Gika D; Moulopoulos LA; Bamia C; Terpos E; Tsionos K; Bamias A
Haematologica; 2006 Jul; 91(7):968-71. PubMed ID: 16757414
[TBL] [Abstract][Full Text] [Related]
32. Bisphosphonate-related osteonecrosis of the jaws--a case report.
Kamoh AK; Ogle O
Compend Contin Educ Dent; 2012 May; 33(5):e74-7. PubMed ID: 23268588
[TBL] [Abstract][Full Text] [Related]
33. Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy.
Vieillard MH; Maes JM; Penel G; Facon T; Magro L; Bonneterre J; Cortet B
Joint Bone Spine; 2008 Jan; 75(1):34-40. PubMed ID: 17981488
[TBL] [Abstract][Full Text] [Related]
34. Platelet-rich plasma improves wound healing in multiple myeloma bisphosphonate-associated osteonecrosis of the jaw patients.
Coviello V; Peluso F; Dehkhargani SZ; Verdugo F; Raffaelli L; Manicone PF; D' Addona A
J Biol Regul Homeost Agents; 2012; 26(1):151-5. PubMed ID: 22475108
[TBL] [Abstract][Full Text] [Related]
35. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphanates.
Pavkovic M; Petrushevska G; Jovanovic R; Karanfilski O; Cevreska L; Stankovic S; Stojanovic A
Prilozi; 2010; 31(2):39-49. PubMed ID: 21258276
[TBL] [Abstract][Full Text] [Related]
36. The status of jaw lesions and medication-related osteonecrosis of jaw in patients with multiple myeloma.
Lu SY; Ma MC; Wang MC; Hsue SS
J Formos Med Assoc; 2021 Nov; 120(11):1967-1976. PubMed ID: 33551311
[TBL] [Abstract][Full Text] [Related]
37. Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer.
Nastro E; Musolino C; Allegra A; Oteri G; Cicciù M; Alonci A; Quartarone E; Alati C; De Ponte FS
Acta Haematol; 2007; 117(3):181-7. PubMed ID: 17164581
[TBL] [Abstract][Full Text] [Related]
38. Oral sodium clodronate induced osteonecrosis of the jaw in a patient with myeloma.
Montazeri AH; Erskine JG; McQuaker IG
Eur J Haematol; 2007 Jul; 79(1):69-71. PubMed ID: 17598839
[TBL] [Abstract][Full Text] [Related]
39. Pharmacogenomics of osteonecrosis of the jaw.
Yang G; Singh S; Chen Y; Hamadeh IS; Langaee T; McDonough CW; Holliday LS; Lamba JK; Moreb JS; Katz J; Gong Y
Bone; 2019 Jul; 124():75-82. PubMed ID: 31022475
[TBL] [Abstract][Full Text] [Related]
40. Identification of Risk Factors for Bisphosphonate-Associated Atypical Femoral Fractures and Osteonecrosis of the Jaw in a Pharmacovigilance Database.
Bejhed RS; Kharazmi M; Hallberg P
Ann Pharmacother; 2016 Aug; 50(8):616-24. PubMed ID: 27179251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
